Tailored chemotherapy based on tumour gene expression analysis: Breast cancer patients' misinterpretations and positive attitudes

European Journal of Cancer Care

Volumn 21, Issue 2, 2012, Pages 242-250

  Pellegrini, I ^a   Rapti, M ^a   Extra, J M ^b   Petri Cal, A ^c   Apostolidis, T ^d   Ferrero, J M ^e   Bachelot, T ^f   Viens, P ^b   Julian Reynier, C ^a   Bertucci, F ^a  

^a INSERM   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c University of Aix Marseille   (France)

^d CENTRE ANTOINE LACASSAGNE   (France)

^e CENTRE LÉON BÉRARD   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Breast cancer; Gene expression analysis; Patients' point of view; Qualitative study; Tailored chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; BREAST TUMOR; CLINICAL TRIAL; FEMALE; FRANCE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ATTITUDE TO HEALTH; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FRANCE; GENE EXPRESSION PROFILING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MIDDLE AGED; QUALITATIVE RESEARCH;

EID: 84857038599     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2011.01300.x     Document Type: Article

References (42)

1. Bertucci F., Nasser V., Granjeaud S., Eisinger F., Adelaide J., Tagett R., Loriod B., Giaconia A., Benziane A., Devilard E., Jacquemier J., Viens P., Nguyen C., Birnbaum D. and Houlgatte R. (2002) Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Human Molecular Genetics 11, 863-872.
2. Bertucci F., Extra J.M., Tarpin C., Tallet A., Lambaudie E. and Viens P. (2009) SA02 trial: a genomics-based prospective study of adjuvant chemotherapy in node-positive early breast cancer with 'good-prognosis signature'. Cancer Research 69 (24 Suppl.), 4041.
3. Bertucci, F., Borie, N., Roche, H., Bachelot, T., Le Doussal, J.M., Macgrogan, G., Debono, S., Martinec, A., Treilleux, I., Finetti, P., Esterni, B., Extra, J.M., Geneve, J., Hermitte, F., Chabannon, C., Jacquemier, J., Martin, A.L., Longy, M., Maraninchi, D., Fert, V., Birnbaum, D. and Viens, P. (2011) Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Research and Treatment 127, 363-373.
4. Bogaerts J., Cardoso F., Buyse M., Braga S., Loi S., Harrison J.A., Bines J., Mook S., Decker N., Ravdin P., Therasse P., Rutgers E., van 't Veer L.J. and Piccart M. (2006) Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nature Clinical Practice. Oncology 3, 540-551.
5. Bueno-de-Mesquita J.M., van Harten W.H., Retel V.P., van't Veer L.J., van Dam F.S., Karsenberg K., Douma K.F., van Tinteren H., Peterse J.L., Wesseling J., Wu T.S., Atsma D., Rutgers E.J., Brink G., Floore A.N., Glas A.M., Roumen R.M., Bellot F.E., van Krimpen C., Rodenhuis S., van de Vijver M.J. and Linn S.C. (2007) Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). The Lancet Oncology 8, 1079-1087.
6. Cappelli M., Surh L., Humphreys L., Verma S., Logan D., Hunter A. and Allanson J. (2001) Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing. Quality of Life Research 10, 595-607.
7. Cardoso F., Van't Veer L., Rutgers E., Loi S., Mook S. and Piccart-Gebhart M.J. (2008) Clinical application of the 70-gene profile: the MINDACT trial. Journal of Clinical Oncology 26, 729-735.
8. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., Karaca G., Troester M.A., Tse C.K., Edmiston S., Deming S.L., Geradts J., Cheang M.C., Nielsen T.O., Moorman P.G., Earp H.S. and Millikan R.C. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502.
9. Chang J.C., Wooten E.C., Tsimelzon A., Hilsenbeck S.G., Gutierrez M.C., Elledge R., Mohsin S., Osborne C.K., Chamness G.C., Allred D.C. and O'Connell P. (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369.
10. EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717.
11. Glaser B.G. and Strauss A.L. (1967) The Discovery of Grounded Theory. Strategies for Qualitative Research. Aldine, Chicago, IL, USA.
12. Henneman L., Timmermans D.R. and van der Wal G. (2004) Public experiences, knowledge and expectations about medical genetics and the use of genetic information. Community Genetics 7, 33-43.
13. Hess K.R., Anderson K., Symmans W.F., Valero V., Ibrahim N., Mejia J.A., Booser D., Theriault R.L., Buzdar A.U., Dempsey P.J., Rouzier R., Sneige N., Ross J.S., Vidaurre T., Gomez H.L., Hortobagyi G.N. and Pusztai L. (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. Journal of Clinical Oncology 24, 4236-4244.
14. Issa A.M., Tufail W., Hutchinson J., Tenorio J. and Baliga M.P. (2009) Assessing patient readiness for the clinical adoption of personalized medicine. Public Health Genomics 12, 163-169.
15. Knauer M., Mook S., Rutgers E.J., Bender R.A., Hauptmann M., van de Vijver M.J., Koornstra R.H., Bueno-de-Mesquita J.M., Linn S.C. and van 't Veer L.J. (2010) The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Research and Treatment 120, 655-661.
16. Liedtke C., Hatzis C., Symmans W.F., Desmedt C., Haibe-Kains B., Valero V., Kuerer H., Hortobagyi G.N., Piccart-Gebhart M., Sotiriou C. and Pusztai L. (2009) Genomic grade index is associated with response to chemotherapy in patients with breast cancer. Journal of Clinical Oncology 27, 3185-3191.
17. Lo S.S., Mumby P.B., Norton J., Rychlik K., Smerage J., Kash J., Chew H.K., Gaynor E.R., Hayes D.F., Epstein A. and Albain K.S. (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. Journal of Clinical Oncology 28, 1671-1676.
18. Ma X.J., Wang Z., Ryan P.D., Isakoff S.J., Barmettler A., Fuller A., Muir B., Mohapatra G., Salunga R., Tuggle J.T., Tran Y., Tran D., Tassin A., Amon P., Wang W., Wang W., Enright E., Stecker K., Estepa-Sabal E., Smith B., Younger J., Balis U., Michaelson J., Bhan A., Habin K., Baer T.M., Brugge J., Haber D.A., Erlander M.G. and Sgroi D.C. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616.
19. Mamounas E.P., Tang G., Fisher B., Paik S., Shak S., Costantino J.P., Watson D., Geyer C.E., Jr, Wickerham D.L. and Wolmark N. (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. Journal of Clinical Oncology 28, 1677-1683.
20. March R., Cheeseman K. and Doherty M. (2001) Pharmacogenetics-legal, ethical and regulatory considerations. Pharmacogenomics 2, 317-327.
21. Moldrup C. (2001) Ethical, social and legal implications of pharmacogenomics: a critical review. Community Genetics 4, 204-214.
22. Nielsen L.F. and Moldrup C. (2006) Lay perspective on pharmacogenomics: a literature review. Personalized Medicine 3, 311-316.
23. O'Neill S.C., Brewer N.T., Lillie S.E., Morrill E.F., Dees E.C., Carey L.A. and Rimer B.K. (2007) Women's interest in gene expression analysis for breast cancer recurrence risk. Journal of Clinical Oncology 25, 4628-4634.
24. Oratz R., Paul D., Cohn A.L. and Sedlacek S.M. (2007) Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. Journal of Oncology Practice 3, 182-186.
25. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., Cronin M., Baehner F.L., Watson D., Bryant J., Costantino J.P., Geyer C.E., Jr, Wickerham D.L. and Wolmark N. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology 24, 3726-3734.
26. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O. and Botstein D. (2000) Molecular portraits of human breast tumours. Nature 406, 747-752.
27. Pope C. and Mays N. (1995) Reaching the parts other methods cannot reach: an introduction to qualitative methods in health and health services research. BMJ 311, 42-45.
28. Retel V.P., Bueno-de-Mesquita J.M., Hummel M.J., van de Vijver M.J., Douma K.F., Karsenberg K., van Dam F.S., van Krimpen C., Bellot F.E., Roumen R.M., Linn S.C. and van Harten W.H. (2009) Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics. International Journal of Technology Assessment in Health Care 25, 73-83.
29. Shaw J.S. and Bassi K.L. (2001) Lay attitudes toward genetic testing for suscdptibility to inherited diseases. Journal of Health Psychology 6, 405-423.
30. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lonning P.E., Brown P.O., Borresen-Dale A.L. and Botstein D. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 100, 8418-8423.
31. Sotiriou C. and Pusztai L. (2009) Gene-expression signatures in breast cancer. The New England Journal of Medicine 360, 790-800.
32. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B., Desmedt C., Larsimont D., Cardoso F., Peterse H., Nuyten D., Buyse M., Van de Vijver M.J., Bergh J., Piccart M. and Delorenzi M. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute 98, 262-272.
33. Sparano J.A. and Paik S. (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. Journal of Clinical Oncology 26, 721-728.
34. Sparano J.A. and Solin L.J. (2010) Defining the clinical utility of gene expression assays in breast cancer: the intersection of science and art in clinical decision making. Journal of Clinical Oncology 28, 1625-1627.
35. Swain S.M. (2006) A step in the right direction. Journal of Clinical Oncology 24, 3717-3718.
36. Symmans W.F., Hatzis C., Sotiriou C., Andre F., Peintinger F., Regitnig P., Daxenbichler G., Desmedt C., Domont J., Marth C., Delaloge S., Bauernhofer T., Valero V., Booser D.J., Hortobagyi G.N. and Pusztai L. (2010) Genomic index of sensitivity to endocrine therapy for breast cancer. Journal of Clinical Oncology 28, 4111-4119.
37. Thorne S., Oliffe J., Kim-Sing C., Hislop T.G., Stajduhar K., Harris S.R., Armstrong E.A. and Oglov V. (2010) Helpful communications during the diagnostic period: an interpretive description of patient preferences. European Journal of Cancer Care 19, 746-754.
38. Turnquist D.C., Harvey J.H. and Andersen B.L. (1988) Attributions and adjustment to life-threatening illness. British Journal of Clinical Psychology 27 (Pt 1), 55-65.
39. Tzeng J.P., Mayer D., Richman A.R., Lipkus I., Han P.K., Valle C.G., Carey L.A. and Brewer N.T. (2010) Women's experiences with genomic testing for breast cancer recurrence risk. Cancer 116, 1992-2000.
40. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R. and Friend S. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
41. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H. and Bernards R. (2002) A gene-expression signature as a predictor of survival in breast cancer. The New England Journal of Medicine 347, 1999-2009.
42. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., Talantov D., Timmermans M., Meijer-van Gelder M.E., Yu J., Jatkoe T., Berns E.M., Atkins D. and Foekens J. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679.